ANKRD27
- Known as:
- ANKRD27
- Catalog number:
- 001625A
- Product Quantity:
- 250ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- ANKRD27
Related genes to: ANKRD27
- Gene:
- ANKRD27 NIH gene
- Name:
- ankyrin repeat domain 27
- Previous symbol:
- -
- Synonyms:
- FLJ00040, DKFZp434L0718, VARP
- Chromosome:
- 19q13.11
- Locus Type:
- gene with protein product
- Date approved:
- 2004-02-11
- Date modifiied:
- 2016-10-05
Related products to: ANKRD27
Related articles to: ANKRD27
- Alzheimer's disease and related dementias (ADRD) and Parkinson's disease and related disorders (PDRD) have substantial genetic contributions, yet the role of rare damaging coding variants remains incompletely characterized at population scale. We performed gene-based burden testing of rare loss-of-function and deleterious missense variants using whole-genome sequencing data from large population biobanks combined with disease-specific sequencing cohorts, leveraging proxy phenotypes to maximize statistical power for late-onset neurodegenerative diseases. We confirmed rare variant burden in established ADRD genes () and PDRD genes (). We additionally identified novel associations in ADRD () and PDRD (). The strongest signal was observed for , where damaging variants clustered within domains mediating interactions with Rab GTPases and retromer components. Our results demonstrate the power of population-scale sequencing combined with proxy phenotypes to identify rare coding risk genes for neurodegenerative diseases. - Source: PubMed
Publication date: 2026/03/04
Le Guen YannPeña-Tauber AndrésPulgrossi Rafael CatoiaPark JunyoungOrias HoldenGreicius Michael D - The escalating prevalence of diabetes-depression comorbidity (DDC) necessitates novel therapies targeting shared pathophysiological pathways, which needs to decipher the underlying molecular mechanisms. This study elucidates the therapeutic potential of chrysophanol, a natural anthraquinone, in streptozotocin (STZ) and chronic unpredictable mild stress (CUMS)-induced DDC rat model. Behavioral assessments, biochemical profiling, and integrated multi-omics analyses (RNA-seq and proteomics) were employed to decipher underlying mechanisms. Successful model establishment was confirmed by prolonged immobility time in the tail suspension test (p < 0.01) and reduced general health scores. Chrysophanol treatment restored serum brain-derived neurotrophic factor (BDNF) levels (p < 0.01) and ameliorated dyslipidemia (total cholesterol: p < 0.05). RNA-seq results revealed that chrysophanol regulated expression of hundreds of genes, which were enriched in synaptic vesicle cycling (downregulation of Sh3gl2, Camk5), CNS myelination, and axonal ensheathment pathways. Proteomic profile demonstrated the suppression of neurodegenerative markers and activation of axonal regeneration pathways. Notably, chrysophanol downregulated synaptic proteins associated with leukocyte chemotaxis (Pla2g7, Mdk) and glutamatergic synapses (Itpr2, Slc1a1) while upregulated axonal development, regeneration, and PPARγ signaling proteins (Apoa4, Apoa1, Apod), suggesting anti-inflammatory effects and disease-modifying potential through synaptic/axonal regulation. Integrated multi-omics identified overlapping targets linked to neuronal repair (Ankrd27) and iron metabolism (Fth1). These findings suggest chrysophanol as a multitarget agent alleviating DDC via synergistic restoration of neuroplasticity, suppression of neuroinflammation, and rebalancing of metabolic homeostasis, implying a mechanistic foundation for developing chrysophanol-based therapies of diabetes-associated neuropsychiatric disorders. - Source: PubMed
Publication date: 2025/11/28
Hu Xue-JianGe DanMa Xiao-LanYang Yan - The plasma proteins are an important source of therapeutic targets. This study aims to address the diagnostic and therapeutic challenges of bladder cancer (BC) by using Mendelian randomization (MR) with a large sample size from multiple centers to identify the plasma proteins which are causally related to the pathogenesis of BC. Followed by merging nine plasma protein datasets from six studies, a total of 5538 plasma proteins and three BC datasets (ieu-b-4874, ukb-b-8193, FinnGen_R11_C3_ BLADDER_EXALL) were used to perform proteome‑wide MR to estimate the contribution of plasma proteins to BC, separately. To ensure the robustness of the results, Veen intersection operation on MR results revealed that 14 meaningful candidate pathogenic plasma proteins (ANKRD27, BIN1, FAHD1, IL17RB, MRPL21, PPT1, PSCA, SLC16A3, SLURP1, SPON2, TACSTD2, TMEM87B, YWHAB) were obtain from three datasets. Then, we validated these proteins through various methods, including meta-analysis, reverse MR, Bayesian co-localization analysis and summary-data-based MR (SMR), and pathogenic plasma proteins were divided into three layers according to the validation confidence. We then performed single-cell transcriptome analysis (Registration number: GSE222315), which showed that 13/14 candidate plasma proteins were expressed and 12 proteins were differentially expressed in at least one cell type. Finally, protein-protein interactions (PPI) analysis and druggability evaluation were performed to explore the relationship between the interaction of plasma protein markers and existing cancer drug targets. Summarily, our research uncovered 14 plasma protein biomarkers linked to BC risk, offering novel perspectives on the etiology and potential targets for developing screening biomarkers and therapeutic drugs for BC. - Source: PubMed
Publication date: 2025/05/02
Cao JinlongChen SiyuWang JirongFan XinpengLiu ShanhuiShan JiaqiLi XiaoranYang Li - Ankyrin repeat domain 27 (ANKRD27) has been found to be associated with certain cancers. However, its clinical potential in pan-cancer remains unclear. - Source: PubMed
Publication date: 2025/01/06
Shen NingzheFan CongcongYing HaosunLi XinmiaoZhang WeizhiYu JingluZheng JianjianLi Yifei - To identify suitable reference genes for gene expression studies in rat dorsal root ganglia (DRG) neurons. - Source: PubMed
Liu FenglanMiao YangWang YaxianShan Qianqian